Correlation between antiplatelet therapy in secondary prevention of acute cerebral infarction and cerebral microbleeds: A susceptibility-weighted imaging (SWI) study
Affiliations: [a] Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, P. R. China
| [b] Department of Physical and Rehabilitation Medicine, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, P. R. China
| [c] Department of Neurology, Baoding First Central Hospital, Baoding, Hebei, P. R. China
Correspondence:
[*]
Corresponding author: Yanhong Dong, Department of Neurology, Hebei General Hospital. No.348 Hepingxi Road, Shijiazhuang, 050051, Hebei, P. R. China. Tel.: +86 13931120897; Fax: +86 0311 85989992; E-mail: [email protected].
Abstract: OBJECTIVE:To investigate the clinical significance of antiplatelet aggregation therapy for patients diagnosed with acute cerebral infarction (ACI) complicated with the cerebral microbleeds (CMBs). METHODS:Thirty patients with ACI and 36 patients with intracerebral hemorrhage (ICH) were included in this research. Two groups, studied by susceptibility-weighted imaging (SWI), were compared in terms of the number, location, and severity of CMBs. Then, 30 cases of ACI patients were divided into CMBs sub-group and non-CMBs sub-group. Univariate analysis between these two sub-groups was performed to determine the risk factors regarding the incidence of CMBs. For ACI patients, the number of CMBs before and after applying anti-platelet treatment were compared to examine the impacts of anti-platelet treatment on hemorrhagic transformation. RESULTS:CMBs were found to be more prevalent and severe in ICH patients than in ACI patients. CMBs in patients with ICH were more severe than in patients with ischemic stroke (IS), which indicates that CMBs closely relate to ICH. Hypertension and leukoaraiosis were found to have significant effects on the incidence of CMBs. After anti-platelet treatment, patients with CMBs (≥5) increased the number of CMB, whereas there was no obvious effect on patients with the CMBs less than 5 or no CMBs. CONCLUSIONS:The number of CMBs increased significantly among ACI patients with 5 or more CMBs before the anti-platelet treatment. CMBs are more frequently found in patients with hemorrhagic stroke than in patients with ischemic stroke, and more severe than the latter, which suggests that the clinical impact of higher association between the increase of the number of the CMBs and the hemorrhagic stroke.
